Cell state dependent effects of Bmal1 on melanoma immunity and tumorigenicity

Xue Zhang,Shishir M. Pant,Cecily C. Ritch,Hsin-Yao Tang,Hongguang Shao,Harsh Dweep,Yao-Yu Gong,Rebekah Brooks,Patricia Brafford,Adam J. Wolpaw,Yool Lee,Ashani Weeraratna,Amita Sehgal,Meenhard Herlyn,Andrew Kossenkov,David Speicher,Peter K. Sorger,Sandro Santagata,Chi V. Dang
DOI: https://doi.org/10.1038/s41467-024-44778-2
IF: 16.6
2024-01-20
Nature Communications
Abstract:Abstract The circadian clock regulator Bmal1 modulates tumorigenesis, but its reported effects are inconsistent. Here, we show that Bmal1 has a context-dependent role in mouse melanoma tumor growth. Loss of Bmal1 in YUMM2.1 or B16-F10 melanoma cells eliminates clock function and diminishes hypoxic gene expression and tumorigenesis, which could be rescued by ectopic expression of HIF1α in YUMM2.1 cells. By contrast, over-expressed wild-type or a transcriptionally inactive mutant Bmal1 non-canonically sequester myosin heavy chain 9 (Myh9) to increase MRTF-SRF activity and AP-1 transcriptional signature, and shift YUMM2.1 cells from a Sox10 high to a Sox9 high immune resistant, mesenchymal cell state that is found in human melanomas. Our work describes a link between Bmal1, Myh9, mouse melanoma cell plasticity, and tumor immunity. This connection may underlie cancer therapeutic resistance and underpin the link between the circadian clock, MRTF-SRF and the cytoskeleton.
multidisciplinary sciences
What problem does this paper attempt to address?